Abstract:Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the comorbidity of these brain disorders in aging individuals represents a significant challenge in basic research and clinical practice. The similarities and differences between stroke and AD in terms of pathogenesis and pathophysiology, however, have rarely been comparably reviewed. Here, we discuss the research background and recent progresses that are important and informative for the comorbidity of stroke and late-onset AD and related dementia (ADRD). Glutamatergic NMDA receptor (NMDAR) activity and NMDAR-mediated Ca2+ influx are essential for neuronal function and cell survival. An ischemic insult, however, can cause rapid increases in glutamate concentration and excessive activation of NMDARs, leading to swift Ca2+ overload in neuronal cells and acute excitotoxicity within hours and days. On the other hand, mild upregulation of NMDAR activity, commonly seen in AD animal models and patients, is not immediately cytotoxic. Sustained NMDAR hyperactivity and Ca2+ dysregulation lasting from months to years, nevertheless, can be pathogenic for slowly evolving events, i.e. degenerative excitotoxicity, in the development of AD/ADRD. Specifically, Ca2+ influx mediated by extrasynaptic NMDARs (eNMDARs) and a downstream pathway mediated by transient receptor potential cation channel subfamily M member (TRPM) are primarily responsible for excitotoxicity. On the other hand, the NMDAR subunit GluN3A plays a "gatekeeper" role in NMDAR activity and a neuroprotective role against both acute and chronic excitotoxicity. Thus, ischemic stroke and AD share an NMDAR- and Ca2+-mediated pathogenic mechanism that provides a common receptor target for preventive and possibly disease-modifying therapies. Memantine (MEM) preferentially blocks eNMDARs and was approved by the Federal Drug Administration (FDA) for symptomatic treatment of moderate-to-severe AD with variable efficacy. According to the pathogenic role of eNMDARs, it is conceivable that MEM and other eNMDAR antagonists should be administered much earlier, preferably during the presymptomatic phases of AD/ADRD. This anti-AD treatment could simultaneously serve as a preconditioning strategy against stroke that attacks ≥ 50% of AD patients. Future research on the regulation of NMDARs, enduring control of eNMDARs, Ca2+ homeostasis, and downstream events will provide a promising opportunity to understand and treat the comorbidity of AD/ADRD and stroke.

Glutamate acts on acid-sensing ion channels to worsen ischaemic brain injury

Glutamate as a co-agonist for acid-sensing ion channels to aggravate ischemic brain damage

Disruption of Auto-Inhibition Underlies Conformational Signaling of ASIC1a to Induce Neuronal Necroptosis

Glutamate excitotoxicity: Potential therapeutic target for ischemic stroke

The Dream Protein Negatively Regulates The Nmda Receptor Through Interaction With The Nr1 Subunit

ASICs Aggravate Acidosis-Induced Injuries During Ischemic Reperfusion

Glutamate Antagonists in Therapy of Stroke

Targeting harmful effects of non-excitatory amino acids as an alternative therapeutic strategy to reduce ischemic damage

Coupling between NMDA receptor and acid-sensing ion channel contributes to ischemic neuronal death.

Increasing glutamate promotes ischemia-reperfusion-induced ventricular arrhythmias in rats in vivo.

Glutamate Receptor-Independent Calcium Toxicity Pathways in Acute Ischemic Brain Injury

Extracellular Spermine Exacerbates Ischemic Neuronal Injury Through Sensitization Of Asic1a Channels To Extracellular Acidosis

Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease

Neuroprotection of GluR5-containing Kainate Receptor Activation against Ischemic Brain Injury through Decreasing Tyrosine Phosphorylation of N-Methyl-d-aspartate Receptors Mediated by Src Kinase

Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor

TRIOL Inhibits Rapid Intracellular Acidification and Cerebral Ischemic Injury: the Role of Glutamate in Neuronal Metabolic Reprogramming

Correction: Tissue Acidosis Induces Neuronal Necroptosis Via ASIC1a Channel Independent of Its Ionic Conduction

The Role of ASICs in Cerebral Ischemia

Knockdown of ASIC2a subunit aggravates injury of rat C6 glioma cells in acidosis

Acute and chronic excitotoxicity in ischemic stroke and late-onset Alzheimer's disease

Effect of Acid-sensing Ion Channels in Ischemic Brain Injury